Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First clinical description of a pedigree with complete NAF1 deletion.
Galtier J, Dimicoli-Salazar S, Trimouille A, Lainey E, Revy P, Bidet A, Vial Y, Forcade E, Negrier-Leibreich ML, Rivière E, Tinat J, Le Meur N, Ménard C, Pigneux A, Leguay T, Dumas PY, Ibrahima B, Kannengiesser C. Galtier J, et al. Among authors: leguay t. Leuk Lymphoma. 2023 Feb;64(2):487-490. doi: 10.1080/10428194.2022.2148377. Epub 2022 Nov 23. Leuk Lymphoma. 2023. PMID: 36416722 No abstract available.
Comparable outcome after related or unrelated allogeneic stem cell transplant following reduced conditioning with fludarabine, busulfan and antithymocyte globulin.
Vigouroux S, Tabrizi R, Melot C, Coiffard J, Lafarge X, Marit G, Bouabdallah K, Pigneux A, Leguay T, Dilhuydy MS, Schmitt A, Boiron JM, Milpied N. Vigouroux S, et al. Among authors: leguay t. Leuk Lymphoma. 2012 Jan;53(1):162-5. doi: 10.3109/10428194.2011.604754. Epub 2011 Aug 18. Leuk Lymphoma. 2012. PMID: 21756024 No abstract available.
Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD.
Labouré G, Dulucq S, Labopin M, Tabrizi R, Guérin E, Pigneux A, Lafarge X, Leguay T, Bouabdallah K, Dilhuydy MS, Duclos C, Lascaux A, Marit G, Mahon FX, Boiron JM, Milpied N, Vigouroux S. Labouré G, et al. Among authors: leguay t. Biol Blood Marrow Transplant. 2012 Dec;18(12):1845-50. doi: 10.1016/j.bbmt.2012.06.012. Epub 2012 Jul 2. Biol Blood Marrow Transplant. 2012. PMID: 22766221 Free article.
Nelarabine for T cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation: an opportunity to improve survival.
Forcade E, Leguay T, Vey N, Baruchel A, Delaunay J, Robin M, Socié G, Dombret H, Peffault de Latour R, Raffoux E. Forcade E, et al. Among authors: leguay t. Biol Blood Marrow Transplant. 2013 Jul;19(7):1124-6. doi: 10.1016/j.bbmt.2013.04.010. Epub 2013 May 3. Biol Blood Marrow Transplant. 2013. PMID: 23648236 Free article.
Risk Factors for Steroid-Refractory Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation from Matched Related or Unrelated Donors.
Calmettes C, Vigouroux S, Labopin M, Tabrizi R, Turlure P, Lafarge X, Marit G, Pigneux A, Leguay T, Bouabdallah K, Dilhuydy MS, Duclos C, Mohr C, Lascaux A, Dumas PY, Dimicoli-Salazar S, Saint-Lézer A, Milpied N. Calmettes C, et al. Among authors: leguay t. Biol Blood Marrow Transplant. 2015 May;21(5):860-5. doi: 10.1016/j.bbmt.2015.01.016. Epub 2015 Jan 21. Biol Blood Marrow Transplant. 2015. PMID: 25617807 Free article.
Severe acute GvHD following administration of ipilimumab for early relapse of AML after haploidentical stem cell transplantation.
Gros FX, Cazaubiel T, Forcade E, Lechevalier N, Leguay T, Servant V, Tabrizi R, Clement L, Dumas PY, Bidet A, Pigneux A, Vigouroux S, Milpied N. Gros FX, et al. Among authors: leguay t. Bone Marrow Transplant. 2017 Jul;52(7):1047-1048. doi: 10.1038/bmt.2017.78. Epub 2017 Jun 5. Bone Marrow Transplant. 2017. PMID: 28581465 No abstract available.
Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia.
Dumas PY, Bertoli S, Bérard E, Médiavilla C, Yon E, Tavitian S, Leguay T, Huguet F, Forcade E, Milpied N, Sarry A, Sauvezie M, Bories P, Pigneux A, Récher C. Dumas PY, et al. Among authors: leguay t. Oncotarget. 2017 Mar 7;8(45):79126-79136. doi: 10.18632/oncotarget.15988. eCollection 2017 Oct 3. Oncotarget. 2017. PMID: 29108292 Free PMC article.
Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis.
Calmettes C, Gabriel F, Blanchard E, Servant V, Bouchet S, Kabore N, Forcade E, Leroyer C, Bidet A, Latrabe V, Leguay T, Vigouroux S, Tabrizi R, Breilh D, Accoceberry I, de Lara MT, Pigneux A, Milpied N, Dumas PY. Calmettes C, et al. Among authors: leguay t. Oncotarget. 2018 Jun 1;9(42):26724-26736. doi: 10.18632/oncotarget.25477. eCollection 2018 Jun 1. Oncotarget. 2018. PMID: 29928481 Free PMC article.
87 results